Search peptides, terms, sources/
Regulatory source · 2024

FDA Briefing Document, Pharmacy Compounding Advisory Committee: CJC-1295-Related Bulk Drug Substances

Document title: FDA Evaluation of CJC-1295-Related Bulk Drug Substances (CJC-1295 (free base), CJC-1295 acetate, CJC-1295 with drug affinity complex (DAC) (free base), CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate (TFA))

About this source

Kind
Regulatory or official document
Design
Regulatory / legislative document
Primary or secondary
secondary
Retraction status
None known
Date checked
15 November 2026

Limitations

US regulatory briefing prepared for an advisory committee; it is not a final FDA determination and is not controlling for UK status. Its safety summary of the healthy-volunteer trials is FDA's reading of published papers, and its account of the 2006 phase 2 death relies on internet reports because the trial data were not published.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.